Dana T. Aftab

TL;DR: The randomised phase 3 METEOR trial compared the efficacy and safety of cabozantinib versus the mTOR inhibitor everolimus in patients with advanced renal cell carcinoma who progressed after previous VEGFR tyrosine-kinase inhibitor treatment.

TL;DR: Findings document that invasion and metastasis are promoted by selective inhibition of VEGF signaling and can be reduced by the concurrent inhibition of c-Met.

TL;DR: Findings indicate that inhibition of c-Met and functionally related kinases amplifies the effects of VEGFR blockade and leads to rapid, robust, and progressive regression of tumor vasculature, increased intratumoral hypoxia and apoptosis, and reduced tumor invasiveness and metastasis.

TL;DR: The CTC0 and CTC conversion end points are robust and meaningful response end points for early-phase metastatic castration-resistant prostate cancer clinical trials and have the highest discriminatory power for overall survival.

TL;DR: Examination of the preclinical potential of a novel, orally bioavailable PI3K/mTOR dual inhibitor in in vitro and in vivo studies shows activity as monotherapy and in combination in a range of genetically diverse GBM xenografts.